Content about Clinical psychology

SAN DIEGO — CVS Caremark announced today its partnership with The Miracle Project, a nonprofit organization that creates social skills programs for children with autism through the performing arts, to expand The Miracle Project School Inclusion Program to public schools in San Diego and San Jose, Calif.

ATLANTA — More than 1-in-10 Americans ages 12 years and older take antidepressants, and the rate of antidepressant use in the United States among all ages increased 400% between 1988 and 2008, according to a new report by the Centers for Disease Control and Prevention's National Center for Health Statistics.

LONDON — One-third of spending on mental health in the United States, or $42 million, goes toward anxiety disorders, according to a new report by Companies & Markets.

The report found that the global anxiety disorders market would likely rise in value to $5.9 billion by 2017, thanks to increasing stress levels exacerbated by an unstable economic climate, the aging of the population, an increase in patients with anxiety disorders and new drug development.

NEW YORK — Such mood disorders as anxiety and depression may be a precursor to diabetes in Latinos, according to a study by University of California at San Diego researchers scheduled for presentation at the American Psychiatric Association’s annual meeting in Honolulu.

As reported in the Los Angeles Times, the researchers found that while Latinos have higher-than-average rates of diabetes, they also seem to have higher-than-average risk of having both diabetes and a mood disorder.

NEW YORK — Drug maker Forest Labs plans to acquire the developer of a recently approved antidepressant.

Forest announced that it would pay $1.2 billion, or $30 per share, to acquire Clinical Data, saying the acquisition would give it control of the drug Viibryd (vilazodone hydrochloride), a treatment for major depressive disorder in adults that won Food and Drug Administration approval last month. The agreement also includes up to $6 per share in addition for milestones related to Viibryd.

WEST LAFAYETTE, Ind. — Spouses of older patients with diabetes tend to experience distress if the diabetic patient has symptoms of depression, according to a new study.

WILMINGTON, Del. AstraZeneca is launching a new campaign focused on depression, the Anglo-Swedish drug maker said Thursday.

The campaign, “Take on Depression,” consists of a Facebook page and Twitter feed designed to provide information on bipolar depression and major depressive disorder.

WALLINGFORD, Conn. HerbaSway has introduced a hangover support in a ready-to-drink single “shot.”

Last Round is a 2.5-oz. bottle that contains such ingredients as kudzu root, stevia and green tea extracts. Last Round works by removing the effects of alcohol, “relaxing” the flow of blood and oxygen to the brain, and detoxifying the body so users avoid headaches, dry mouth and other ailments associated with hangovers, the company said. HerbaSway also recommended drinking one 2.5-oz. bottle of Last Round just before bedtime.

BOSTON A new study conducted by investigators at Harvard Medical School and Massachusetts General Hospital suggested that the dietary supplement S-adenosylmethionine (SAMe) can be an effective, relatively well-tolerated, adjunctive treatment for adults with major depressive disorders who do not respond to their treatment with antidepressant medication, Pharmavite announced Tuesday.

WASHINGTON More than 300 medications for treating mental disorders are in development, according to a new report by a pharmaceutical industry lobbying group.